Literature DB >> 34846643

Cancer metabolism and tumor microenvironment: fostering each other?

Yiyuan Yuan1, Huimin Li2, Wang Pu3, Leilei Chen3, Dong Guo4, Hongfei Jiang4, Bo He5, Siyuan Qin5, Kui Wang5, Na Li6, Jingwei Feng7, Jing Wen2,8, Shipeng Cheng2,8, Yaguang Zhang2,8, Weiwei Yang9, Dan Ye10, Zhimin Lu11, Canhua Huang12, Jun Mei13, Hua-Feng Zhang14, Ping Gao15, Peng Jiang16, Shicheng Su17, Bing Sun18,19, Shi-Min Zhao20.   

Abstract

The changes associated with malignancy are not only in cancer cells but also in environment in which cancer cells live. Metabolic reprogramming supports tumor cell high demand of biogenesis for their rapid proliferation, and helps tumor cell to survive under certain genetic or environmental stresses. Emerging evidence suggests that metabolic alteration is ultimately and tightly associated with genetic changes, in particular the dysregulation of key oncogenic and tumor suppressive signaling pathways. Cancer cells activate HIF signaling even in the presence of oxygen and in the absence of growth factor stimulation. This cancer metabolic phenotype, described firstly by German physiologist Otto Warburg, insures enhanced glycolytic metabolism for the biosynthesis of macromolecules. The conception of metabolite signaling, i.e., metabolites are regulators of cell signaling, provides novel insights into how reactive oxygen species (ROS) and other metabolites deregulation may regulate redox homeostasis, epigenetics, and proliferation of cancer cells. Moreover, the unveiling of noncanonical functions of metabolic enzymes, such as the moonlighting functions of phosphoglycerate kinase 1 (PGK1), reassures the importance of metabolism in cancer development. The metabolic, microRNAs, and ncRNAs alterations in cancer cells can be sorted and delivered either to intercellular matrix or to cancer adjacent cells to shape cancer microenvironment via media such as exosome. Among them, cancer microenvironmental cells are immune cells which exert profound effects on cancer cells. Understanding of all these processes is a prerequisite for the development of a more effective strategy to contain cancers.
© 2022. Science China Press and Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  cancer immunology; cancer metabolism; cancer microenvironment; epigenetics

Mesh:

Substances:

Year:  2021        PMID: 34846643     DOI: 10.1007/s11427-021-1999-2

Source DB:  PubMed          Journal:  Sci China Life Sci        ISSN: 1674-7305            Impact factor:   6.038


  431 in total

1.  First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma.

Authors:  Bryan G Allen; Kellie L Bodeker; Mark C Smith; Varun Monga; Sonia Sandhu; Raymond Hohl; Thomas Carlisle; Heather Brown; Nancy Hollenbeck; Sandy Vollstedt; Jeremy D Greenlee; Matthew A Howard; Kranti A Mapuskar; Steven N Seyedin; Joseph M Caster; Karra A Jones; Joseph J Cullen; Daniel Berg; Brett A Wagner; Garry R Buettner; Mindi J TenNapel; Brian J Smith; Douglas R Spitz; John M Buatti
Journal:  Clin Cancer Res       Date:  2019-08-19       Impact factor: 12.531

2.  Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses.

Authors:  Dimitrios Anastasiou; George Poulogiannis; John M Asara; Matthew B Boxer; Jian-kang Jiang; Min Shen; Gary Bellinger; Atsuo T Sasaki; Jason W Locasale; Douglas S Auld; Craig J Thomas; Matthew G Vander Heiden; Lewis C Cantley
Journal:  Science       Date:  2011-11-03       Impact factor: 47.728

3.  ROS-mediated p53 induction of Lpin1 regulates fatty acid oxidation in response to nutritional stress.

Authors:  Wissam Assaily; Daniel A Rubinger; Keith Wheaton; Yunping Lin; Weili Ma; Wanli Xuan; Lauren Brown-Endres; Katsuya Tsuchihara; Tak W Mak; Samuel Benchimol
Journal:  Mol Cell       Date:  2011-11-04       Impact factor: 17.970

4.  Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments.

Authors:  Alessia Angelin; Luis Gil-de-Gómez; Satinder Dahiya; Jing Jiao; Lili Guo; Matthew H Levine; Zhonglin Wang; William J Quinn; Piotr K Kopinski; Liqing Wang; Tatiana Akimova; Yujie Liu; Tricia R Bhatti; Rongxiang Han; Benjamin L Laskin; Joseph A Baur; Ian A Blair; Douglas C Wallace; Wayne W Hancock; Ulf H Beier
Journal:  Cell Metab       Date:  2017-04-13       Impact factor: 27.287

5.  Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency.

Authors:  N A Alam; A J Rowan; N C Wortham; P J Pollard; M Mitchell; J P Tyrer; E Barclay; E Calonje; S Manek; S J Adams; P W Bowers; N P Burrows; R Charles-Holmes; L J Cook; B M Daly; G P Ford; L C Fuller; S E Hadfield-Jones; N Hardwick; A S Highet; M Keefe; S P MacDonald-Hull; E D A Potts; M Crone; S Wilkinson; F Camacho-Martinez; S Jablonska; R Ratnavel; A MacDonald; R J Mann; K Grice; G Guillet; M S Lewis-Jones; H McGrath; D C Seukeran; P J Morrison; S Fleming; S Rahman; D Kelsell; I Leigh; S Olpin; I P M Tomlinson
Journal:  Hum Mol Genet       Date:  2003-06-01       Impact factor: 6.150

Review 6.  Immunity, inflammation and cancer: a leading role for adenosine.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Nat Rev Cancer       Date:  2013-11-14       Impact factor: 60.716

7.  Glioblastoma-Associated Microglia Reprogramming Is Mediated by Functional Transfer of Extracellular miR-21.

Authors:  Erik R Abels; Sybren L N Maas; Lisa Nieland; Zhiyun Wei; Pike See Cheah; Eric Tai; Christy-Joy Kolsteeg; Sophie A Dusoswa; David T Ting; Suzanne Hickman; Joseph El Khoury; Anna M Krichevsky; Marike L D Broekman; Xandra O Breakefield
Journal:  Cell Rep       Date:  2019-09-17       Impact factor: 9.423

Review 8.  The molecular hallmarks of epigenetic control.

Authors:  C David Allis; Thomas Jenuwein
Journal:  Nat Rev Genet       Date:  2016-06-27       Impact factor: 53.242

9.  Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1.

Authors:  Chi Lam Au Yeung; Ngai-Na Co; Tetsushi Tsuruga; Tsz-Lun Yeung; Suet-Ying Kwan; Cecilia S Leung; Yong Li; Edward S Lu; Kenny Kwan; Kwong-Kwok Wong; Rosemarie Schmandt; Karen H Lu; Samuel C Mok
Journal:  Nat Commun       Date:  2016-03-29       Impact factor: 14.919

10.  Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation.

Authors:  Nicholas Arpaia; Clarissa Campbell; Xiying Fan; Stanislav Dikiy; Joris van der Veeken; Paul deRoos; Hui Liu; Justin R Cross; Klaus Pfeffer; Paul J Coffer; Alexander Y Rudensky
Journal:  Nature       Date:  2013-11-13       Impact factor: 49.962

View more
  7 in total

1.  CREB1 contributes colorectal cancer cell plasticity by regulating lncRNA CCAT1 and NF-κB pathways.

Authors:  Bin Li; Lisi Zheng; Jiayi Ye; Chenmin Zhang; Jie Zhou; Qiaojuan Huang; Yanhua Guo; Luqin Wang; Peng Yu; Shurong Liu; Qiao Lin; Yuxia Luo; Hui Zhou; Jianhua Yang; Lianghu Qu
Journal:  Sci China Life Sci       Date:  2022-06-10       Impact factor: 10.372

2.  Circ_0000705 facilitates proline metabolism of esophageal squamous cell carcinoma cells by targeting miR-621/PYCR1 axis.

Authors:  Cui-Juan Qian; Yi-Yang Tong; Lin-Ken Wu; Yi-Chao Wang; Xiao-Sheng Teng; Jun Yao
Journal:  Discov Oncol       Date:  2022-06-22

3.  CRISPR-Cas9-based genome-wide screening identified novel targets for treating sorafenib-resistant hepatocellular carcinoma: a cross-talk between FGF21 and the NRF2 pathway.

Authors:  Jiang Chen; Shi Jiang; Huijiang Shao; Bixia Li; Tong Ji; Daniel Staiculescu; Jiayan He; Jie Zhao; Liuxin Cai; Xiao Liang; Junjie Xu; Xiujun Cai
Journal:  Sci China Life Sci       Date:  2022-04-01       Impact factor: 10.372

Review 4.  Progress of Nanomaterials in Photodynamic Therapy Against Tumor.

Authors:  Lei Chen; Jiahui Huang; Xiaotong Li; Miaoting Huang; Shaoting Zeng; Jiayi Zheng; Shuyi Peng; Shiying Li
Journal:  Front Bioeng Biotechnol       Date:  2022-05-31

5.  Systemic Analyses of the Expression of TPI1 and Its Associations with Tumor Microenvironment in Lung Adenocarcinoma and Squamous Cell Carcinoma.

Authors:  Xiaodong Yang; Cong Ye; Hui Zheng; Chenyang Dai; Yuming Zhu
Journal:  Dis Markers       Date:  2022-01-25       Impact factor: 3.434

Review 6.  Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses.

Authors:  Pedro Barrios-Bernal; Zyanya Lucia Zatarain-Barrón; Norma Hernández-Pedro; Mario Orozco-Morales; Alejandra Olivera-Ramírez; Federico Ávila-Moreno; Ana Laura Colín-González; Andrés F Cardona; Rafael Rosell; Oscar Arrieta
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-24

7.  Bioinformatics Analysis of LGR4 in Colon Adenocarcinoma as Potential Diagnostic Biomarker, Therapeutic Target and Promoting Immune Cell Infiltration.

Authors:  Lijuan Wu; Xiaoxiao Tian; Hao Du; Xiaomin Liu; Haigang Wu
Journal:  Biomolecules       Date:  2022-08-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.